New Delhi: Amid a controversy, the Center has said that India has not banned the export of vaccines for Kovit-19, but has imposed restrictions on an Indian company that is expected to be a leader in providing vaccines to developing countries.
India, the world’s largest vaccine producer, is expected to play a key role as low- and middle-income countries look forward to launching immunization programs to contain the epidemic.
But following emergency approval by Indian authorities for the British-made AstraZeneca and another vaccine developed domestically on Sunday, media reports said India would not allow exports for several months.
The government has not banned the export of one of the COVID vaccines. That fact must be taken into account. “Rajesh Bhushan, a senior official in the health ministry, told reporters that he was warning against calling it” misinformation “.
In a joint statement on Tuesday, two vaccine makers – Serum Institute of India and Bharat Biotech – also pledged global access to the dose, saying the most important task was to save lives and livelihoods in India and around the world.
Currently, the global focus is mainly on the serum manufacturer of the Astrogenega vaccine – the company is on track to reach one billion doses this year as it raises its current capacity from 60 to 70 million doses to 100 per month. A company spokesman said the dose was one million by March.
It has already saved 50 million doses made before approval.
Early vaccines are expected to be given locally, with the aim of vaccinating 300 million people by August, which will require millions of doses for its own population.
However, the release in many countries in Asia and Africa depends on the speed at which vaccines are received from Indian companies such as the Serum Company. Half of the one billion dollars contracted is to be sold to developing countries.
Health experts are also monitoring the growth of two local vaccine candidates by Indian companies.
Andrea D., assistant director of the Duke Innovation Global Health Center. According to Taylor, “India’s leadership in this front could be a game changer for the Govt vaccine distribution in developing countries. “First is the amount of vaccines they want to produce, as well as the substantial amount of drugs that have already been prepared and stockpiled and are now ready to ship.”
While rich countries such as the United States, the United Kingdom and Canada are launching immunization programs with vaccines available for their own people, developing countries are lagging behind as they look for affordable vaccine supplies.
According to them, the most promising candidate so far is AstraZeneca, which can be stored in ordinary refrigerators and is cheaper compared to vaccines such as Pfizer and Moderna.
Kavi, a non-profit global vaccine alliance, has been contracted with Serum to be the “vaccine for the world” for 200 million doses of astrogen. It is expected to cost around $ 3.
However, it is not clear when these will be available. Although Indian companies, which make up 60 per cent of the world’s vaccines, are increasing excise taxes, it is expected that there will be a major mismatch between supply and demand amid the global struggle for vaccines.
“Our data on vaccine procurement and production show that there are reasons to be concerned that low- and middle-income countries will not receive adequate vaccines by 2021,” says Taylor. “This is not due to the hoarding of the Indian market, but globally we cannot produce fast enough or ensure that all the people with the highest priority are reached first.”